Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR: BULLS AND BEARS! -- Ignore unavailable to you. Want to Upgrade?

To: DAN LITTLE who wrote (5791)	5/3/1998 11:23:00 AM
From: OLD JAKE JUSTUS	Respond to of 8902

Good reporting, Dan! Dr. H has recently removed any doubt that I might have had about him or the company. He has made a total believer out of me. I predict that he is going to make a lot of believers out of many of those, so-called, doubting-Thomases', before much longer. In my personal opinion: Only a complete and total fool, if not a complete idiot, could not see the future astronomical potential for ADVANCED VIRAL RESEARCH CORPORATION. With millions of lives that can potentially be saved, by giving the sick folks that need the "new potential wonder drug", Reticulose; and with COMMERCIAL SALES estimated to be in the billions over the next 3 to 5 years, it is hard for me to understand how anyone could poke fun at this company. Dr. H is reportedly making giant leaps forward and the full impact of this progress will soon be known and felt by all of the ADVR shareholders! It must be a person living in the past, that holds a vendetta or grudge against, Mr. Bill Bregman and ADVR, who could resort to those kind of tactics. How this person, who seems to be living in the past, and who will probably, eventually finish last, could do a thing such as poke fun at Dr. H'S laudable endeavors, is beyond me. I won't even make much account of the fact that this person appears to ME to be totally ignorant of the present-day pertinent facts about this company. It seems to me that he won't even try to find out the potential of the company, or what has been happening over the past year and a half. He seems to be living in the past! IGNORANT: Uninformed: Unaware that Advanced Viral Research Corporation is making great strides under Dr. Shalom Z. Hirschman's leadership. I am aware that this person is plenty smart. I have never stated that he was not a smart person, except in this present case with ADVR. His views and remarks, on ADVR, to me, are not that of a rational person. I am well aware the he is entitled to express his opinion on this subject. He may even, eventually, state that he was only joking all of the time! However, I am, also, aware that I, too, can express my opinion on this subject. My opinion is that if his posts are all jokes, then I find most of them hard to laugh at. This is my opinion and I firmly believe that what I have stated is the "nature of the beast." I could be wrong, but I don't think so. "We see how much a man has, and therefore we envy him; if we saw how little that he enjoys, we should rather pity him." JEREMIAH SPEED

To: DAN LITTLE who wrote (5791)	5/3/1998 11:55:00 PM
From: s martin	Read Replies (2) \| Respond to of 8902

>>Jake, in the last SEC filing it stated that ADVR had recieved about 4 million in financing last year. I take that to mean that the RBB deal is completed. The Yonkers lab, Argentina trials, Safety test, and wages should account for about 2 million. That leaves about 2 million in the bank. << Dan your figures do not compute with the SEC filing which says they lost/spent over 4 million last year. During the year ended December 31, 1997, the Company incurred a loss of $4,141,729 ($.00 per share) compared to $1,154,740 ($.00 per share) in 1996. The Company's increased losses for the year ended December 31, 1997 as compared with the year ended December 31, 1996 were attributable primarily to the employment of Shalom Z. Hirschman, M.D. as President and Chief Executive Officer of the Company ($325,000 for 1997 vs $68,750 for 1996), interest charges as a result of the beneficial conversion feature associated with the February Debenture and the October Debenture ($1,626,368 for 1997 vs $0 for 1996), increased research and development expense ($817,603 for 1997 vs $255,600 for 1996), opening and maintenance costs of the Company's Yonkers, NY office ($57,000 for 1997 vs $0 for 1996), and the implementation of Statement of Financial Accounting Standards Board (SFAS) No. 123, "Accounting for Stock-Based Compensati ion," which accounted for Options granted and recorded as compensation expense ($399,322 for 1997 vs $287,341 for 1996). Administrative expenses and the lack of sales revenues and comtibuted to the company's losses.